Table 1.
Predicted Rank | Repositioned drugs | Repositioning score (mean) | Repositioning score (std) | Status* |
---|---|---|---|---|
1 | raloxifene 0.0000001 | 0.85 | 0.77 | FDA CT |
2 | paclitaxel 0.0000046 | 2.75 | 1.01 | FDA CT |
3 | tamoxifen 0.000001 | 3.43 | 1.97 | FDA CT |
4 | paclitaxel 0.0000001 | 5.46 | 33.73 | FDA CT |
5 | fulvestrant 0.000001 | 6.31 | 0.98 | FDA CT |
6 | exemestane 0.00000001 | 21.82 | 86.28 | FDA CT |
7 | letrozole 0.000014 | 26.43 | 96.52 | FDA CT |
8 | sulindac 0.00005 | 29.02 | 18.10 | CT |
9 | fulvestrant 0.00000001 | 31.01 | 42.76 | FDA CT |
10 | daunorubicin 0.000007 | 37.95 | 83.48 | |
11 | clomifene 0.0000066 | 38.97 | 20.41 | |
12 | sulindac 0.0001 | 46.48 | 19.31 | CT |
13 | estradiol 0.00000001 | 53.47 | 79.65 | FDA CT |
14 | imatinib 0.00001 | 55.64 | 68.28 | CT |
15 | estradiol 0.0000001 | 58.60 | 30.09 | FDA CT |
16 | methotrexate 0.0000088 | 59.80 | 127.82 | FDA CT |
17 | bezafibrate 0.000011 | 68.08 | 139.31 | |
18 | doxorubicin 0.0000068 | 70.22 | 218.72 | FDA CT |
19 | valproic acid 0.00005 | 76.00 | 69.52 | |
20 | raloxifene 0.0000078 | 80.74 | 84.14 | FDA CT |
21 | amiloride 0.0000132 | 113.04 | 193.55 | |
22 | tamoxifen 0.000007 | 124.33 | 137.36 | FDA CT |
FDA: FDA-approved breast cancer drug, CT: Clinical trial breast cancer drug